Perinatal transmission of hepatitis B virus in highincidence countries

https://doi.org/10.1016/0166-0934(87)90070-XGet rights and content

Abstract

Hepatitis B is a serious public health problem throughout the world. Hepatitis B virus (HBV) induces acute hepatitis with a case-fatality rate of about 1%. Even more important, 5–10% of patients infected with HBV become chronic carriers and about 25% of these will die due to cirrhosis and hepatocellular carcinoma. The reservoir of HBV chronic carriers in the world is estimated at more than 200 million people and 80% of them reside in Asia and the western Pacific.

In high-incidence areas, such as south-east Asia, perinatal transmission of HBV from carrier mothers to newborns appears to be the most important factor for the high prevalence of HBV infection and 70–90% of infants born to HBsAg/HBeAg-positive mothers become chronic carriers. Three possibilities of transmission of HBV from carrier mothers to newborns are suggested: (a) transplacental transmission in utero — it was estimated that such transmission occurred in 5–15% of newborns; (b) transmission during delivery, which is considered the main mode of perinatal transmission; (c) postnatal transmission from mother to newborn, which is not common. HBeAg is the main maternal factor in determining whether infection of newborns will occur; the expression of this antigen seems to be determined genetically.

Recently it has been shown that immunoprophylaxis is highly effective in preventing the development of the carrier state in infants born to HBsAg/HBeAg-positive mothers. Only 5–10% of high-risk infants are not protected by vaccination. If it becomes possible to immunize the entire world population including all babies born to carrier mothers at birth, and if our knowledge of the mechanisms of perinatal transmission of HBV is accurate, the carriers and acute cases of HB ought to disappear in two to three generations.

References (63)

  • C. Rosendahl et al.

    Avoidance of perinatal transmission of hepatitis B virus: is passive immunization always necessary?

    Lancet

    (1983)
  • P. Rubinstein et al.

    HLA and hepatitis B responsiveness. Comparative studies in vaccine recipients and in persistent antigen and antibody carriers

    Hum. Immunol.

    (1982)
  • I.L. Schweitzer et al.

    Viral hepatitis B in neonates and infants

    Am. J. Med.

    (1973)
  • V.C.V. Wong et al.

    Prevention of the HBsAg carrier state in newborn infants of the Ag HBs carriers by administration of hepatitis B vaccine and HBIg

    Lancet

    (1984)
  • K.E. Anderson et al.

    Australian antigen in infants bom to mothers with chronic Australia antigenaemia in Taiwan

    Am. J. Dis. Child.

    (1975)
  • R.P. Beasley

    Hepatitis B virus as the etiological agent in hepatocellular carcinoma — epidemiologic considerations

    Hepatology

    (1982)
  • R.P. Beasley et al.

    The e antigen and vertical transmission of hepatitis B surface antigen

    Am. J. Epidemiol.

    (1977)
  • R.P. Beasley et al.

    Hepatitis B immune globulin efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state

    Lancet

    (1981)
  • R.P. Beasley et al.

    Incidence of hepatitis B virus infection in preschool children in Taiwan

    J. Inf. Dis.

    (1982)
  • R.P. Beasley et al.

    Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the HBV carrier state. Final report of a randomized double blind placebo-controlled trial

    Hepatology

    (1983)
  • E.H. Boxall

    Maternal transmission of hepatitis B

  • E.H. Boxall et al.

    Hepatitis B vaccine in the prevention of perinatally transmitted hepatitis B virus infection: initial report of a study in the West Midlands of England

    J. Med. Virol.

    (1986)
  • A. Carbonara et al.

    Endemic HBV infection, tissue autoantibodies and HLA analysis of a Sardinian population

    Tissue Antigens

    (1983)
  • S.H. Chan et al.

    Maternal-child hepatitis B virus transmission in Singapore

    Int. J. Epidemiol.

    (1985)
  • P. Coursaget et al.

    Simultaneous administration of diphtheria-tetanus-pertussis-polio and hepatitis B vaccines in a simplified immunization program: immune response to diphtheria toxoid, tetanus toxoid, pertussis, and hepatitis B surface antigen

    Infect. Immun.

    (1986)
  • F. Deinhardt et al.

    Viral hepatitis

  • F. Deinhardt et al.

    Viral hepatitis

    WHO Chron.

    (1983)
  • A. Derso et al.

    Transmission of HBsAg from mother to infant in four ethnic groups

    Br. Med. J.

    (1978)
  • J.I. Esteban et al.

    Immunoprophylaxis of perinatal transmission of the hepatitis B virus: efficacy of hepatitis B vaccine in a low-prevalence area

    J. Med. Virol.

    (1986)
  • A. Goudeau et al.

    Prevention of hepatitis B virus infection in children born to HBsAg-positive/HBeAg-positive mothers

    Develop. Biol. Stand.

    (1983)
  • L. Gross

    Oncogenic viruses

    (1970)

    • Cited by (76)

    • Hepatitis B vaccine response among infants born to hepatitis B surface antigen-positive women

      2014, Vaccine
      Citation Excerpt :

      Annually, approximately 25,000 infants are born to hepatitis B surface antigen (HBsAg)-positive women in the United States [1]. Perinatal hepatitis B virus (HBV) transmission is an important mode of infection [2–4] with up to 90% of perinatal HBV infections becoming chronic, and 25% risk of progression to liver cancer and premature death [5–8]. In 1984, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) recommended infants born to HBsAg-positive women receive post-exposure prophylaxis (PEP) [9].

    • Seroprotection after recombinant hepatitis B vaccination among newborn infants: A review

      2013, Vaccine
      Citation Excerpt :

      Pregnant women with acute or chronic HBV infection are an important source of hepatitis B for their infants. Although a small proportion of infants are infected in utero, exposure to blood or body fluids during birth is a major route of transmission for HBV infection among infants [3]. Early life transmission also occurs through contact with infected siblings or care providers who may be unaware of their infection [4–8].

    • Antenatal lamivudine to reduce perinatal hepatitis B transmission: A cost-effectiveness analysis

      2012, American Journal of Obstetrics and Gynecology
      Citation Excerpt :

      Thus, our estimate of the relative risk of perinatal transmission was 0.38 in patients treated with antenatal lamivudine. In addition, because our model assumed that neonates born to mothers with hepatitis B received both the hepatitis B vaccine series and the hepatitis B immune globulin, we approximated the perinatal transmission rate to be 5% (a range of 3–10% was used in the sensitivity analysis).9,12-15 We chose to offer lamivudine to all hepatitis B women regardless of e antigen positivity, appreciating that if the analysis for the whole group proved to be cost-effective, offering it to only those at highest risk (hepatitis B e antigen positive) would certainly be even more cost-effective.

    • An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus

      2022, Journal of Clinical Gastroenterology

    • Hepatitis B Related Liver Cirrhosis in Oman

      2022, Oman Medical Journal

    • Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy

      2022, Hepatology International
    View all citing articles on Scopus
    View full text
    Copyright © 1987 Published by Elsevier B.V.